AusPAR: Nuvaxovid

Australian Public Assessment Report

AusPAR

AusPAR: Nuvaxovid [PDF, 1.07 MB]

AusPAR: Nuvaxovid [Word, 3.02 MB]

Attachment: Product Information: Nuvaxovid [PDF, 369.57 KB]

Attachment: Product Information: Nuvaxovid [Word, 81.16 KB]

Device/Product Name

Nuvaxovid

Active ingredients

SARS-CoV-2 rS with Matrix M adjuvant (NVX-CoV2373)

AusPAR Date

26 July 2022

Published

29 July 2022

Submission Number

PM-2022-01431-1-2

Submission Type

Extension of indications

Decision

Approved for provisional registration